2010 Immunization Vaccines 
European Pharmaceutical Review
JULY 12, 2023
The first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive ® has been developed through a 13-year collaboration between the world’s largest vaccine manufacturer Serum Institute of India Pvt.
European Pharmaceutical Review
AUGUST 26, 2022
Moderna has filed patent infringement lawsuits alleging that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty ® infringes patents Moderna filed between 2010 and 2016 covering its foundational messenger RNA (mRNA) technology. ” But why sue now? .” ” But why sue now?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 28, 2022
On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20.
Omnicell
SEPTEMBER 5, 2022
Ken Perez VP of Healthcare Policy Omnicell The Democrats’ recent sweep of the United States Senate Georgia runoff elections means the Democrats will control both chambers of Congress as well as the White House for the first time since 2010.
Roots Analysis
OCTOBER 30, 2023
The next generation RNA therapeutics and RNA vaccines pipeline currently features the presence of more than 20 circular RNA therapeutics and vaccines, being developed across initial stages of drug development (discovery and preclinical).
pharmaphorum
OCTOBER 12, 2022
Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines. Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”.
pharmaphorum
DECEMBER 23, 2022
In the last few years, the first generation of cell therapies has offered a powerful new way of treating blood cancers, with CAR-T technology reprogramming patients’ immune system to fight cancer. The post After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer appeared first on.
Expert insights. Personalized for you.
98 
Let's personalize your content